Abstract
Summary
The Middle East and Africa bladder cancer diagnostics market is projected to register a substantial CAGR of 6.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Middle East and Africa Bladder Cancer Diagnostics Market, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and the rest of the Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Middle East and Africa bladder cancer diagnostics market are:
• Rising incidence of bladder cancer globally
• Rising awareness for the early diagnosis of bladder cancer
Market Players:
Some of the key market players for the Middle East and Africa bladder cancer diagnostics market are listed below:
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Koninklijke Philips N.V.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• FUJIFILM Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Siemens Healthcare GmbH
• BD
• Neusoft Corporation
• Abbott
• General Electric Company
• Hologic
• QIAGEN
• Cepheid.
• Ambu A/S
• Time Medical Holding.
• MinFound Medical Systems Co., Ltd.
Table of Contents
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET 26
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 TEST TYPE SEGMENT LIFELINE CURVE 37
2.8 MARKET END USER COVERAGE GRID 38
2.9 DBMR MARKET POSITION GRID 39
2.10 VENDOR SHARE ANALYSIS 40
2.11 SECONDARY SOURCES 41
2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTLE ANALYSIS 45
4.2 PORTER'S FIVE FORCES MODEL 46
5 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 47
6 REGULATORY FRAMEWORK 49
7 MARKET OVERVIEW 50
7.1 DRIVERS 52
7.1.1 RISING INCIDENCE OF BLADDER CANCER MIDDLE EAST & AFRICALY 52
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 52
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 53
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 53
7.2 RESTRAINTS 54
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 54
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 54
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 54
7.3 OPPORTUNITIES 55
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 55
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 55
7.3.3 INCREASE IN THE GERIATRIC POPULATION 56
7.4 CHALLENGES 56
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 56
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 57
8 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 58
8.1 OVERVIEW 59
8.2 CYSTOSCOPY 62
8.3 URINE LAB TEST 62
8.3.1 URINE CYTOLOGY 64
8.3.2 URINALYSIS 64
8.3.3 URINE TUMOR MARKER TEST 64
8.3.4 URINE CULTURE 64
8.3.5 OTHERS 64
8.4 BIOPSY 64
8.5 IMAGING TEST 65
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 66
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 66
8.5.3 ULTRASOUND 66
8.5.4 INTRAVENOUS PYELOGRAM (IVP) 67
8.6 OTHERS 67
9 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 68
9.1 OVERVIEW 69
9.2 STAGE IV 72
9.3 STAGE III 72
9.4 STAGE II 73
9.5 STAGE I 74
10 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 76
10.1 OVERVIEW 77
10.2 TRANSITIONAL CELL BLADDER CANCER 80
10.3 SQUAMOUS CELL BLADDER CANCER 81
10.4 OTHER CANCER TYPES 82
11 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 83
11.1 OVERVIEW 84
11.2 HOSPITAL 87
11.3 DIAGNOSTIC IMAGING CENTERS 87
11.4 CANCER RESEARCH INSTITUTES 88
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 89
11.6 ASSOCIATED LABS 90
12 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 91
12.1 OVERVIEW 92
12.2 DIRECT TENDER 95
12.3 RETAIL SALES 95
13 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 97
13.1 MIDDLE EAST AND AFRICA 98
13.1.1 SOUTH AFRICA 105
13.1.2 SAUDI ARABIA 107
13.1.3 U.A.E 109
13.1.4 EGYPT 111
13.1.5 ISRAEL 113
13.1.6 REST OF MIDDLE EAST AND AFRICA 115
14 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 116
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 116
15 SWOT ANALYSIS 117
16 MIDDLE EAST & AFRICA BLADDER CANCER DIAGNOSTICS MARKET 118
16.1 F. HOFFMANN- LA ROCHE LTD 118
16.1.1 COMPANY SNAPSHOT 118
16.1.2 REVENUE ANALYSIS 118
16.1.3 COMPANY SHARE ANALYSIS 119
16.1.4 PRODUCT PORTFOLIO 119
16.1.5 RECENT DEVELOPMENTS 119
16.2 MERCK KGAA 120
16.2.1 COMPANY SNAPSHOT 120
16.2.2 REVENUE ANALYSIS 120
16.2.3 COMPANY SHARE ANALYSIS 121
16.2.4 PRODUCT PORTFOLIO 121
16.2.5 RECENT DEVELOPMENT 121
16.3 THERMO FISHER SCIENTIFIC INC 122
16.3.1 COMPANY SNAPSHOT 122
16.3.2 REVENUE ANALYSIS 122
16.3.3 COMPANY SHARE ANALYSIS 123
16.3.4 PRODUCT PORTFOLIO 123
16.3.5 RECENT DEVELOPMENT 123
16.4 KONINLIJKE PHILIPS N.V 124
16.4.1 COMPANY SNAPSHOT 124
16.4.2 REVENUE ANALYSIS 124
16.4.3 COMPANY SHARE ANALYSIS 125
16.4.4 PRODUCT PORTFOLIO 125
16.4.5 RECENT DEVELOPMENT 125
16.5 BIO-RAD LABORATORIES, INC 126
16.5.1 COMPANY SNAPSHOT 126
16.5.2 COMPANY SNAPSHOT 126
16.5.3 COMPANY SHARE ANALYSIS 127
16.5.4 PRODUCT PORTFOLIO 127
16.5.5 RECENT DEVELOPMENT 127
16.6 ABBOTT 128
16.6.1 COMPANY SNAPSHOT 128
16.6.2 REVENUE ANALYSIS 128
16.6.3 PRODUCT PORTFOLIO 129
16.6.4 RECENT DEVELOPMENT 129
16.7 AGILENT TECHNOLOGIES, INC 130
16.7.1 COMPANY SNAPSHOT 130
16.7.2 REVENUE ANALYSIS 130
16.7.3 PRODUCT PORTFOLIO 131
16.7.4 RECENT DEVELOPMENT 131
16.8 AMBU A/S 132
16.8.1 COMPANY SNAPSHOT 132
16.8.2 REVENUE ANALYSIS 132
16.8.3 PRODUCT PORTFOLIO 133
16.8.4 RECENT DEVELOPMENT 133
16.9 BD 134
16.9.1 COMPANY SNAPSHOT 134
16.9.2 REVENUE ANALYSIS 134
16.9.3 PRODUCT PORTFOLIO 135
16.9.4 RECENT DEVELOPMENT 135
16.10 CANON MEDICAL SYSTEMS CORPORATION 136
16.10.1 COMPANY SNAPSHOT 136
16.10.2 REVENUE ANALYSIS 136
16.10.3 PRODUCT PORTFOLIO 137
16.10.4 RECENT DEVELOPMENT 137
16.11 CEPHEID 138
16.11.1 COMPANY SNAPSHOT 138
16.11.2 REVENUE ANALYSIS 138
16.11.3 PRODUCT PORTFOLIO 139
16.11.4 RECENT DEVELOPMENTS 139
16.12 FUJIFILM CORPORATION 140
16.12.1 COMPANY SNAPSHOT 140
16.12.2 REVENUE ANALYSIS 140
16.12.3 PRODUCT PORTFOLIO 141
16.12.4 RECENT DEVELOPMENTS 141
16.13 GENERAL ELECTRIC COMPANY 142
16.13.1 COMPANY SNAPSHOT 142
16.13.2 REVENUE ANALYSIS 142
16.13.3 PRODUCT PORTFOLIO 143
16.13.4 RECENT DEVELOPMENTS 143
16.14 HOLOGIC INC 144
16.14.1 COMPANY SNAPSHOT 144
16.14.2 REVENUE ANALYSIS 144
16.14.3 PRODUCT PORTFOLIO 145
16.14.4 RECENT DEVELOPMENT 145
16.15 ILLUMINA INC 146
16.15.1 COMPANY SNAPSHOT 146
16.15.2 REVENUE ANALYSIS 146
16.15.3 PRODUCT PORTFOLIO 147
16.15.4 RECENT DEVELOPMENTS 147
16.16 MINFOUND MEDICAL SYSTEMS CO 148
16.16.1 COMPANY SNAPSHOT 148
16.16.2 PRODUCT PORTFOLIO 148
16.16.3 RECENT DEVELOPMENTS 148
16.17 NEUSOFT CORPORATION 149
16.17.1 COMPANY SNAPSHOT 149
16.17.2 COMPANY SNAPSHOT 149
16.17.3 PRODUCT PORTFOLIO 150
16.17.4 RECENT DEVELOPMENT 150
16.18 QIAGEN 151
16.18.1 COMPANY SNAPSHOT 151
16.18.2 REVENUE ANALYSIS 151
16.18.3 PRODUCT PORTFOLIO 152
16.18.4 RECENT DEVELOPMENT 152
16.19 SIEMENS HEALTHCARE GMBH 153
16.19.1 COMPANY SNAPSHOT 153
16.19.2 REVENUE ANALYSIS 153
16.19.3 PRODUCT PORTFOLIO 154
16.19.4 RECENT DEVELOPMENT 155
16.20 TIME MEDICAL HOLDING 156
16.20.1 COMPANY SNAPSHOT 156
16.20.2 PRODUCT PORTFOLIO 156
16.20.3 RECENT DEVELOPMENTS 156
17 QUESTIONNAIRE 157
18 RELATED REPORTS 160